Narrative review of Europe-licensed anti-asthmatic biologics for severe pediatric asthma notes limited pediatric evidence

This narrative review addresses the application of Europe-licensed anti-asthmatic biologics specifically for pediatric patients with severe asthma. The scope of the article is limited by the lack of primary trial data provided in the source text. The authors synthesize the current landscape by noting that the majority of available studies and clinical trials have focused on adults. This focus leaves a relevant gap in pediatric-specific evidence regarding these therapies. No specific sample sizes, primary outcomes, or secondary outcomes are reported in the source material. Furthermore, safety data including adverse events, serious adverse events, discontinuations, and tolerability are not reported for this specific population. The review does not provide pooled effect sizes or specific efficacy metrics. The setting for the discussed evidence is Europe, but detailed intervention or comparator information is not reported. The authors acknowledge the uncertainty surrounding the evidence base for children compared to adults. Practice relevance is not explicitly detailed in the source text. Clinicians should interpret these findings with caution given the absence of direct pediatric data.